Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.140
0.00 (0.00%)
Aug 28, 2026, 2:49 PM EDT - Market open
Cocrystal Pharma Revenue
Cocrystal Pharma had revenue of $105.00K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $330.00K.
Revenue (ttm)
$330.00K
Revenue Growth
n/a
P/S Ratio
65.96
Revenue / Employee
$33,000
Employees
10
Market Cap
21.96M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 2.01M | -4.55M | -69.32% |
| Dec 31, 2019 | 6.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 78.00K | 69.00K | 766.67% |
| Dec 31, 2014 | 9.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 12.61M | -2.65M | -17.36% |
| Dec 31, 2010 | 15.25M | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cerenome | 4.20M |
| Dyadic International | 3.80M |
| Longeveron | 1.19M |
| ABVC BioPharma | 797.92K |
| Allarity Therapeutics | 345.00K |
| Neuphoria Therapeutics | -13.27K |
COCP News
- 11 days ago - Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors - GlobeNewsWire
- 25 days ago - Cocrystal Pharma announces $5M investment from Opko Health - TheFly
- 25 days ago - Cocrystal Pharma announces $5M private placement with Opko Health - TheFly
- 25 days ago - Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health - GlobeNewsWire
- 3 months ago - Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds - TheFly
- 3 months ago - Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer - GlobeNewsWire
- 3 months ago - Cocrystal Pharma announces discovery of pan-viral inhibitors targeting viruses - TheFly
- 3 months ago - Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza - GlobeNewsWire